Literature DB >> 20139698

Lung cancer: a modified epigenome.

Arnaud Van Den Broeck1, Peggy Ozenne, Beatrice Eymin, Sylvie Gazzeri.   

Abstract

Epigenetic is the study of heritable changes in gene expression that occur without changes in DNA sequence. This process is important for gene expression and genome stability and its disruption is now thought to play a key role in the onset and progression of numerous tumor types. The most studied epigenetic phenomena includes post-translational modifications in DNA and histone proteins as well as microRN As expression. As epigenetic aberrations are potentially reversible, their correction has emerged as a potential strategy for the treatment of cancer. This review highlights the roles of chromatin epigenetic modifications and of microRN As expression in lung tumorigenesis and discusses the emerging epigenetic therapies which are being developed for the treatment of lung cancer.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20139698      PMCID: PMC2852567          DOI: 10.4161/cam.4.1.10885

Source DB:  PubMed          Journal:  Cell Adh Migr        ISSN: 1933-6918            Impact factor:   3.405


  96 in total

1.  RAS is regulated by the let-7 microRNA family.

Authors:  Steven M Johnson; Helge Grosshans; Jaclyn Shingara; Mike Byrom; Rich Jarvis; Angie Cheng; Emmanuel Labourier; Kristy L Reinert; David Brown; Frank J Slack
Journal:  Cell       Date:  2005-03-11       Impact factor: 41.582

2.  Genome-wide allelotyping of lung cancer identifies new regions of allelic loss, differences between small cell lung cancer and non-small cell lung cancer, and loci clustering.

Authors:  L Girard; S Zöchbauer-Müller; A K Virmani; A F Gazdar; J D Minna
Journal:  Cancer Res       Date:  2000-09-01       Impact factor: 12.701

3.  Chromatin remodeling factors and BRM/BRG1 expression as prognostic indicators in non-small cell lung cancer.

Authors:  Junya Fukuoka; Takeshi Fujii; Joanna H Shih; Tatiana Dracheva; Daoud Meerzaman; Audrey Player; Kyeong Hong; Sharon Settnek; Ajay Gupta; Kenneth Buetow; Stephen Hewitt; William D Travis; Jin Jen
Journal:  Clin Cancer Res       Date:  2004-07-01       Impact factor: 12.531

4.  Unique microRNA molecular profiles in lung cancer diagnosis and prognosis.

Authors:  Nozomu Yanaihara; Natasha Caplen; Elise Bowman; Masahiro Seike; Kensuke Kumamoto; Ming Yi; Robert M Stephens; Aikou Okamoto; Jun Yokota; Tadao Tanaka; George Adrian Calin; Chang-Gong Liu; Carlo M Croce; Curtis C Harris
Journal:  Cancer Cell       Date:  2006-03       Impact factor: 31.743

5.  Reduced expression of the let-7 microRNAs in human lung cancers in association with shortened postoperative survival.

Authors:  Junichi Takamizawa; Hiroyuki Konishi; Kiyoshi Yanagisawa; Shuta Tomida; Hirotaka Osada; Hideki Endoh; Tomoko Harano; Yasushi Yatabe; Masato Nagino; Yuji Nimura; Tetsuya Mitsudomi; Takashi Takahashi
Journal:  Cancer Res       Date:  2004-06-01       Impact factor: 12.701

6.  DNA methylation markers and early recurrence in stage I lung cancer.

Authors:  Malcolm V Brock; Craig M Hooker; Emi Ota-Machida; Yu Han; Mingzhou Guo; Stephen Ames; Sabine Glöckner; Steven Piantadosi; Edward Gabrielson; Genevieve Pridham; Kristen Pelosky; Steven A Belinsky; Stephen C Yang; Stephen B Baylin; James G Herman
Journal:  N Engl J Med       Date:  2008-03-13       Impact factor: 91.245

7.  Global levels of histone modifications predict prognosis in different cancers.

Authors:  David B Seligson; Steve Horvath; Matthew A McBrian; Vei Mah; Hong Yu; Sheila Tze; Qun Wang; David Chia; Lee Goodglick; Siavash K Kurdistani
Journal:  Am J Pathol       Date:  2009-04-06       Impact factor: 4.307

8.  Reduced expression of class II histone deacetylase genes is associated with poor prognosis in lung cancer patients.

Authors:  Hirotaka Osada; Yoshio Tatematsu; Hiroko Saito; Yasushi Yatabe; Tetsuya Mitsudomi; Takashi Takahashi
Journal:  Int J Cancer       Date:  2004-10-20       Impact factor: 7.396

9.  Loss of BRG1/BRM in human lung cancer cell lines and primary lung cancers: correlation with poor prognosis.

Authors:  David N Reisman; Janiece Sciarrotta; Weidong Wang; William K Funkhouser; Bernard E Weissman
Journal:  Cancer Res       Date:  2003-02-01       Impact factor: 12.701

10.  Aberrant DNA methylation of OLIG1, a novel prognostic factor in non-small cell lung cancer.

Authors:  Romulo M Brena; Carl Morrison; Sandya Liyanarachchi; David Jarjoura; Ramana V Davuluri; Gregory A Otterson; David Reisman; Selina Glaros; Laura J Rush; Christoph Plass
Journal:  PLoS Med       Date:  2007-03-27       Impact factor: 11.069

View more
  11 in total

1.  Promoter methylation-mediated downregulation of PRDM5 contributes to the development of lung squamous cell carcinoma.

Authors:  Shuang-Xiang Tan; Rui-Cheng Hu; Yong-Li Tan; Jing-Jing Liu; Wen-En Liu
Journal:  Tumour Biol       Date:  2014-01-07

2.  miR-196b Is Epigenetically Silenced during the Premalignant Stage of Lung Carcinogenesis.

Authors:  Carmen S Tellez; Daniel E Juri; Kieu Do; Maria A Picchi; Teresa Wang; Gang Liu; Avrum Spira; Steven A Belinsky
Journal:  Cancer Res       Date:  2016-06-14       Impact factor: 12.701

3.  Cigarette smoke induces distinct histone modifications in lung cells: implications for the pathogenesis of COPD and lung cancer.

Authors:  Isaac K Sundar; Michael Z Nevid; Alan E Friedman; Irfan Rahman
Journal:  J Proteome Res       Date:  2013-12-13       Impact factor: 4.466

4.  An integrated analysis of miRNA and mRNA expressions in non-small cell lung cancers.

Authors:  Lina Ma; Yanyan Huang; Wangyu Zhu; Shiquan Zhou; Jihang Zhou; Fang Zeng; Xiaoguang Liu; Yongkui Zhang; Jun Yu
Journal:  PLoS One       Date:  2011-10-27       Impact factor: 3.240

5.  miR-96 induces cisplatin chemoresistance in non-small cell lung cancer cells by downregulating SAMD9.

Authors:  Lin Wu; Xingxiang Pu; Qianzhi Wang; Jun Cao; Fang Xu; L I Xu; Kang Li
Journal:  Oncol Lett       Date:  2015-12-03       Impact factor: 2.967

6.  Tri-methylation of H3K79 is decreased in TGF-β1-induced epithelial-to-mesenchymal transition in lung cancer.

Authors:  Emilie Evanno; Julie Godet; Nathalie Piccirilli; Joëlle Guilhot; Serge Milin; Jean Marc Gombert; Benoit Fouchaq; Joëlle Roche
Journal:  Clin Epigenetics       Date:  2017-08-08       Impact factor: 6.551

7.  Global Decrease of Histone H3K27 Acetylation in ZEB1-Induced Epithelial to Mesenchymal Transition in Lung Cancer Cells.

Authors:  Joëlle Roche; Patrick Nasarre; Robert Gemmill; Aleksander Baldys; Julien Pontis; Christopher Korch; Joëlle Guilhot; Slimane Ait-Si-Ali; Harry Drabkin
Journal:  Cancers (Basel)       Date:  2013-04-03       Impact factor: 6.639

8.  Cellular localization of protein arginine methyltransferase-5 correlates with grade of lung tumors.

Authors:  Konstantin Shilo; Xin Wu; Smita Sharma; Meng Welliver; Wenrui Duan; Miguel Villalona-Calero; Junya Fukuoka; Said Sif; Robert Baiocchi; Charles L Hitchcock; Weiqiang Zhao; Gregory A Otterson
Journal:  Diagn Pathol       Date:  2013-12-10       Impact factor: 2.644

Review 9.  Epigenetic Regulation of the Epithelial to Mesenchymal Transition in Lung Cancer.

Authors:  Joëlle Roche; Robert M Gemmill; Harry A Drabkin
Journal:  Cancers (Basel)       Date:  2017-06-24       Impact factor: 6.639

10.  Epigenetic silencing of miR-493 increases the resistance to cisplatin in lung cancer by targeting tongue cancer resistance-related protein 1(TCRP1).

Authors:  Yixue Gu; Zhijie Zhang; Jiang Yin; Jiahui Ye; Yin Song; Hao Liu; Yan Xiong; Minying Lu; Guopei Zheng; Zhimin He
Journal:  J Exp Clin Cancer Res       Date:  2017-08-31
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.